Literature DB >> 12536246

Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.

Brigid Joseph1, Kuldeep K Bhargava, Harmeet Malhi, Michael L Schilsky, Diwakar Jain, Christopher J Palestro, Sanjeev Gupta.   

Abstract

Technetium-99m sestamibi has attracted interest for assessment of the function of P-glycoproteins, which are well expressed in the liver and have roles in biliary transport and the removal of chemotherapeutic drugs. To further examine the cross-reactivity of (99m)Tc-sestamibi for P-glycoprotein family members, we conducted studies in animals. Hepatobiliary secretion of (99m)Tc-sestamibi was determined in normal FVB/N mice, mutant mice with specific P-glycoprotein deficiencies in the FVB/N background, normal Long-Evans Agouti (LEA) rats, and Long-Evans Cinnamon (LEC) rats with abnormal copper transport and liver disease but intact P-glycoprotein expression. After intrasplenic injection, (99m)Tc-sestamibi was rapidly incorporated in the mouse and rat liver, with maximal accumulation after 102+/-31 and 109+/-16 s, respectively ( P=NS). In normal mice and rats, 55%+/-11% and 55%+/-6%, respectively, of the maximal sestamibi activity was retained in the liver after 1 h ( P=NS). In double knockout mice lacking both mdr1a and mdr1b homologs of the human MDR1 ( ABCB1) gene, 88%+/-11% of maximal sestamibi activity was retained in the liver after 1 h ( P<0.001). In knockout mice deficient in either mdr1a gene or mdr2 ( ABCB4) gene, biliary sestamibi excretion was also impaired, although this impairment was relatively less pronounced in ABCB4-deficient mice than in double knockout mice lacking both ABCB1 gene homologs ( P<0.03). Hepatobiliary sestamibi excretion in LEC rats was not different from that in control normal rats, despite the presence of significant liver disease in the former. Hepatobiliary sestamibi excretion requires P-glycoproteins and is unperturbed in chronic liver disease. Sestamibi appears to be a substrate for both ABCB1 and ABCB4 genes, although the former utilizes it far more efficiently. Assessment of P-glycoprotein activity with sestamibi should consider how regulation of ABCB1 and related family members might modulate sestamibi incorporation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12536246     DOI: 10.1007/s00259-002-1111-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  51 in total

1.  Bone marrow uptake of 99mTc-MIBI in patients with multiple myeloma.

Authors:  R Fonti; S Del Vecchio; A Zannetti; A De Renzo; F Di Gennaro; L Catalano; C Califano; L Pace; B Rotoli; M Salvatore
Journal:  Eur J Nucl Med       Date:  2001-02

2.  Hepatic iron deprivation prevents spontaneous development of fulminant hepatitis and liver cancer in Long-Evans Cinnamon rats.

Authors:  J Kato; M Kobune; Y Kohgo; N Sugawara; H Hisai; T Nakamura; S Sakamaki; N Sawada; Y Niitsu
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

3.  Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16.

Authors:  I Sugawara; I Kataoka; Y Morishita; H Hamada; T Tsuruo; S Itoyama; S Mori
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

4.  Mdr1b facilitates p53-mediated cell death and p53 is required for Mdr1b upregulation in vivo.

Authors:  V Lecureur; J V Thottassery; D Sun; E G Schuetz; J Lahti; G P Zambetti; J D Schuetz
Journal:  Oncogene       Date:  2001-01-18       Impact factor: 9.867

5.  Biliary copper excretion capacity in intact animals: correlation between ATP7B function, hepatic mass, and biliary copper excretion.

Authors:  M L Schilsky; A N Irani; G R Gorla; I Volenberg; S Gupta
Journal:  J Biochem Mol Toxicol       Date:  2000       Impact factor: 3.642

6.  Effects of MDR1 and MDR3 P-glycoproteins, MRP1, and BCRP/MXR/ABCP on the transport of (99m)Tc-tetrofosmin.

Authors:  W S Chen; K E Luker; J L Dahlheimer; C M Pica; G D Luker; D Piwnica-Worms
Journal:  Biochem Pharmacol       Date:  2000-08-01       Impact factor: 5.858

7.  Comparison between 201Tl-chloride and 99Tc(m)-sestamibi SPET brain imaging for differentiating intracranial lymphoma from non-malignant lesions in AIDS patients.

Authors:  S Y Naddaf; M F Akisik; M Aziz; W S Omar; A Hirschfeld; J Masdeu; H Donnenfeld; H M Abdel-Dayem
Journal:  Nucl Med Commun       Date:  1998-01       Impact factor: 1.690

8.  Hepatocyte-specific localization and copper-dependent trafficking of the Wilson's disease protein in the liver.

Authors:  M Schaefer; R G Hopkins; M L Failla; J D Gitlin
Journal:  Am J Physiol       Date:  1999-03

9.  Uptake of cationic technetium complexes in cultured human carcinoma cells and human xenografts.

Authors:  E Barbarics; J F Kronauge; A Davison; A G Jones
Journal:  Nucl Med Biol       Date:  1998-10       Impact factor: 2.408

Review 10.  Transcriptional regulators of the human multidrug resistance 1 gene: recent views.

Authors:  Stéphane Labialle; Landry Gayet; Eric Marthinet; Dominique Rigal; Loris G Baggetto
Journal:  Biochem Pharmacol       Date:  2002-09       Impact factor: 5.858

View more
  5 in total

1.  Abnormal intense skeletal radiotracer uptake on myocardial perfusion imaging with Tc-99m sestamibi.

Authors:  Archana Gowda; Lisa Peddinghaus; Vijay Shandilya; Anna Gavriluke; Diwakar Jain
Journal:  J Nucl Cardiol       Date:  2006 May-Jun       Impact factor: 5.952

2.  Effect of cyclosporin A administration on the biodistribution and multipinhole muSPECT imaging of [123I]R91150 in rodent brain.

Authors:  P Blanckaert; I Burvenich; S Staelens; S De Bruyne; L Moerman; L Wyffels; F De Vos
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

3.  Systemic and local release of inflammatory cytokines regulates hepatobiliary excretion of 99mTc-mebrofenin.

Authors:  Brigid Joseph; Kuldeep K Bhargava; Gene G Tronco; Christopher J Palestro; Sanjeev Gupta
Journal:  Nucl Med Commun       Date:  2008-04       Impact factor: 1.690

Review 4.  Imaging of multidrug resistance in cancer.

Authors:  S Dizdarevic; A M Peters
Journal:  Cancer Imaging       Date:  2011-03-01       Impact factor: 3.909

5.  Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma.

Authors:  Paul R Territo; Mary Maluccio; Amanda A Riley; Brian P McCarthy; James Fletcher; Mark Tann; Romil Saxena; Nicholas J Skill
Journal:  BMC Med Imaging       Date:  2015-05-16       Impact factor: 1.930

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.